Miguel Cuevas1, Alejandra de-la-Torre2, Andrea Córdoba3. 1. a Ocular Immunology Department , School of Medicine, CES University , Medellín , Colombia. 2. b Immunology Department, School of Medicine and Health Sciences , Neuroscience Research Group, NeURos, Rosario University , Bogotá , Colombia. 3. c Ophthalmology Department , School of Medicine, CES University , Medellín , Colombia.
Abstract
PURPOSE: To describe severe bilateral iris depigmentation and persistent ocular hypotony as end-stage manifestations of untreated Vogt-Koyanagi-Harada disease. METHODS: We present the clinical findings and diagnostic studies performed for three patients with bilateral iris depigmentation. RESULTS: Vogt-Koyanagi-Harada disease in late recurrent stage was diagnosed in three patients with bilateral severe iris depigmentation and persistent ocular hypotony. CONCLUSIONS: Early diagnosis and treatment of inflammation are crucial factors in the clinical outcome of Vogt-Koyanagi-Harada disease. When left undiagnosed and untreated from early stages, severe iris depigmentation and ocular hypotony, uncommon manifestations of this disease, can develop.
PURPOSE: To describe severe bilateral iris depigmentation and persistent ocular hypotony as end-stage manifestations of untreated Vogt-Koyanagi-Harada disease. METHODS: We present the clinical findings and diagnostic studies performed for three patients with bilateral iris depigmentation. RESULTS:Vogt-Koyanagi-Harada disease in late recurrent stage was diagnosed in three patients with bilateral severe iris depigmentation and persistent ocular hypotony. CONCLUSIONS: Early diagnosis and treatment of inflammation are crucial factors in the clinical outcome of Vogt-Koyanagi-Harada disease. When left undiagnosed and untreated from early stages, severe iris depigmentation and ocular hypotony, uncommon manifestations of this disease, can develop.